Breast Surgery
Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial.
24 Jan, 2022 | 08:08h | UTCOutcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Related:
Commentary on Twitter:
In MINDACT, 15% of the pts (n=1000) had an ultra-low 70-gene signature. Although some had tumors >2 cm (20%) & were LN+ (20%), prognosis was outstanding
8-year DMFI 97%
8-year BCSS 99.6%Most of these patients received adj treatment. Did they need it?https://t.co/V9SH2StuQE
— Paolo Tarantino (@PTarantinoMD) January 22, 2022
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
20 Jan, 2022 | 08:57h | UTC
Commentary on Twitter
Out on @JCO_ASCO the new ASCO/OH guidelines for adjuvant bisphosphonates in BC
Important to weight risks and benefits based on the risk profile of the disease, financial toxicity, drug availability, patient preferences, comorbidities & life expectancy. https://t.co/6noyYplALB
— Paolo Tarantino (@PTarantinoMD) January 18, 2022
RCT: In premenopausal women with breast cancer, gonadotropin-releasing hormone analogs may preserve ovarian function against chemotherapy-induced gonadotoxic effects.
11 Jan, 2022 | 02:26h | UTCEffects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Randomized clinical trial finds administration of gonadotropin-releasing hormone analogs (GnRHa) with chemotherapy in premenopausal pts with #BreastCancer reduces risk of premature ovarian insufficiency (#POI) and promotes recovery of ovarian function. https://t.co/gymbKT9GWZ pic.twitter.com/OUOlIwPSsq
— JAMA Oncology (@JAMAOnc) December 30, 2021
RCT: In patients presenting with metastatic breast cancer, early locoregional therapy for the primary site did not improve survival or quality of life.
11 Jan, 2022 | 02:29h | UTCEarly Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Systematic Review: Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer.
9 Dec, 2021 | 10:08h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/ccaneloa/status/1464655542010494981
RCT: 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.
2 Dec, 2021 | 09:49h | UTC21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among postmenopausal women with HR–positive, HER2-negative breast cancer, 1-3 positive lymph nodes, and a 21-gene recurrence score of 25 or lower, 5-year invasive disease–free survival was similar whether they received endocrine or chemoendocrine therapy. https://t.co/aZLXBvSHHl pic.twitter.com/EBVnMkGHx4
— NEJM (@NEJM) December 2, 2021
Advances in Breast Cancer Radiotherapy: Implications for Current and Future Practice.
30 Nov, 2021 | 09:55h | UTC
Commentary on Twitter
Advances in #BreastCancer radiotherapy allow shorter regimens and reduced toxicities. This #JCOOP Clinical review summarizes the latest evidence in #radonc for #bcsm @CshahMD ➡️ https://t.co/JxvU5FSQlv pic.twitter.com/GOcwAFJzRm
— Journal of Clinical Oncology (@JCO_ASCO) October 31, 2021
RCT: An exercise program reduced upper limb disability one year after non-reconstructive breast cancer surgery.
18 Nov, 2021 | 08:39h | UTCCommentaries:
Exercise reduces upper limb disability after breast cancer surgery – BMJ / News Medical
Exercise Helps Ease Arm, Shoulder Pain After Breast Cancer Surgery- HealthDay
Structured Exercise Improves Upper Limb Function After Breast Ca Surgery – Physician’s Weekly
Commentary on Twitter
Women who exercise shortly after having non-reconstructive breast cancer surgery appear to regain better shoulder and arm mobility and experience less pain than those who receive standard care, finds this study @jxbruce https://t.co/BhIKb8RRjV
— The BMJ (@bmj_latest) November 11, 2021
Review: Treatment landscape of triple-negative breast cancer — expanded options, evolving needs.
16 Nov, 2021 | 08:23h | UTCTreatment landscape of triple-negative breast cancer — expanded options, evolving needs – Nature Reviews Clinical Oncology (free for a limited period)
Commentary on Twitter
A Review in @NatRevClinOncol describes the current and upcoming therapeutic landscape of triple-negative breast cancer. https://t.co/bcFTef01t1 pic.twitter.com/zFPyeeCnD5
— Nature Portfolio (@NaturePortfolio) November 15, 2021
Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer.
11 Nov, 2021 | 08:32h | UTC
Large observational study suggests prolactin-increasing antipsychotics are associated with increased risk of breast cancer (OR=1.56 for over 5 years of exposure); prolactin-sparing antipsychotics (including clozapine, quetiapine, or aripiprazole), on the other hand, were not associated with increased risk.
10 Nov, 2021 | 06:57h | UTCAntipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
Nested case-control study: ≥5 years exposure to prolactin-sparing APDs was not associated with an increased risk of breast cancer vs.<1 year exposure (aOR=1.19; 0.90–1.58). The opposite was observed with APDs that increase prolactin (aOR=1.56; 1.27–1.92) https://t.co/LwCVyTH051
— P𝘧OL (@psychopharmacol) September 12, 2021
RCT: Elective internal mammary node irradiation does not increase disease-free survival or overall survival in most women with node-positive breast cancer.
27 Oct, 2021 | 01:28h | UTCEffect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial – JAMA Oncology (free for a limited period)
Commentary: No Survival Benefit for Internal Mammary Node Irradiation in Breast Cancer — Women with medially or centrally located tumors may be candidates, however, says researcher – MedPage Today (free registration required)
Commentary on Twitter
Phase III randomized study evaluated the role of internal mammary node irradiation (IMNI) in node-positive #breastcancer. IMNI did not improve the DFS in unselected patients, but did improve DFS in patients with medially or centrally located tumors https://t.co/tw4ZrHn5wn pic.twitter.com/34ye3TR9MA
— JAMA Oncology (@JAMAOnc) October 25, 2021
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
21 Oct, 2021 | 09:48h | UTCPress release: metastatic breast cancer: new ESMO guideline with evidence-based recommendations – European Society of Medical Oncology
Case series: Assessment of silicone particle migration among women undergoing removal or revision of silicone breast implants in the Netherlands.
21 Sep, 2021 | 08:59h | UTCInvited commentary: Silicone Breast Implants and Disease—Many Questions Unanswered
Commentary on Twitter
In this case series including women w noncohesive or cohesive silicone gel breast implants, silicone leakage occurred in 98.8% of women, indicating silicone gel bleed, and in 86.6% of women, migration of silicone particles outside the capsule was detected. https://t.co/tyCpLw565Z
— JAMA Network Open (@JAMANetworkOpen) September 20, 2021
Systematic Review: Partial breast irradiation versus whole breast radiotherapy for early breast cancer.
15 Sep, 2021 | 08:46h | UTC
Commentary on Twitter
https://twitter.com/CochraneUK/status/1433703573402046467
Long-term report of study evaluating radiation following surgical excision for good-risk ductal carcinoma in situ.
14 Sep, 2021 | 08:44h | UTC
Commentary on Twitter
At 15 years, NRG-RTOG 9804 "good risk" breast #DCIS trial shows advantage of radiation therapy over observation to reduce #breastcancer risk https://t.co/l5OWVOb5Dg
#JCO #BCSM #radonc @NRGOnc; @MSK_RadOnc pic.twitter.com/TPAZRheoHT— Journal of Clinical Oncology (@JCO_ASCO) September 10, 2021
Systematic review finds there is insufficient evidence that AI breast cancer screening is accurate enough to replace human scrutiny.
10 Sep, 2021 | 05:12h | UTCOriginal study: Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy – The BMJ
Commentary on Twitter
A systematic review of #AI for mammography is very disappointing
"Thirty four (94%) of 36 AI systems evaluated in these studies were less accurate than a single radiologist, and all were less accurate than consensus of two or more radiologists"https://t.co/zqFTxojU9J @bmj_latest pic.twitter.com/wylwOsf4ua— Eric Topol (@EricTopol) September 2, 2021
Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging.
25 Aug, 2021 | 08:59h | UTCRelated:
2 Case Series and Guidance| Lymphadenopathy in COVID-19 Vaccine Recipients
COVID-19 vaccine-linked adenopathies could mimic breast malignancies
Cohort study: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers.
20 Aug, 2021 | 08:39h | UTC
Commentary on Twitter
For #BRCA1 mutation carriers, longer duration of oral contraceptive use (>10 yr) is associated with a greater reduction in #OvarianCancer risk, and the protection is long term. https://t.co/HrrutgaYKX
— Anna Chichura, MD (@AnnaChichuraMD) July 3, 2021
Oncoplastic breast surgery: A guide to good practice.
19 Aug, 2021 | 08:40h | UTCOncoplastic breast surgery: A guide to good practice – European Journal of Surgical Oncology
Mammographic features are associated with cardiometabolic disease risk and mortality.
6 Aug, 2021 | 09:04h | UTC
ASCO Guideline Update: Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer.
30 Jul, 2021 | 11:51h | UTC
RCT: Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer.
30 Jul, 2021 | 11:43h | UTC
Commentary on Twitter
In postmenopausal women with hormone-receptor-positive breast cancer who had 5 yrs of AI, extending adjuvant endocrine therapy by 5 years provides no benefit over a 2-year extension but is associated with a greater risk of bone fracturehttps://t.co/YDxeQVu8B9
— K Pavithran (@drkpavithran) July 29, 2021
Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.
30 Jul, 2021 | 11:49h | UTC
Systematic review: Breast Reconstruction After Mastectomy.
22 Jul, 2021 | 10:45h | UTCBreast Reconstruction After Mastectomy – Agency for Healthcare Research and Quality